349099-89-4

Basic information

• Product Name: N-(3,4-dichlorophenyl)-5-fluoro-2-hydroxybenzamide
• Synonyms: N-(3,4-Dichlorophenyl)-5-fluoro-2-hydroxybenzamide;Benzamide, N-(3,4-dichlorophenyl)-5-fluoro-2-hydroxy-
• CAS NO: 349099-89-4
• Molecular Formula: C₁₃H₈Cl₂FNO₂
• Molecular Weight: 300.1125
• Mol File: 349099-89-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 366.8°C at 760 mmHg
• Flash Point: 175.7°C
• Density: 1.54g/cm³
• Vapor Pressure: 6.74E-06mmHg at 25°C
• Refractive Index: 1.666
• PKA: 8.04±0.43(Predicted)
• CAS DataBase Reference: N-(3,4-dichlorophenyl)-5-fluoro-2-hydroxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-dichlorophenyl)-5-fluoro-2-hydroxybenzamide(349099-89-4)
• EPA Substance Registry System: N-(3,4-dichlorophenyl)-5-fluoro-2-hydroxybenzamide(349099-89-4)

Safety Data

• Hazardous Substances Data: 349099-89-4(Hazardous Substances Data)

Relevant articles and documents

INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA

Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.